189 related articles for article (PubMed ID: 35747941)
61. Discovery of WD-890: A novel allosteric TYK2 inhibitor for the treatment of multiple autoimmune diseases.
Fang Z; Sun H; Wang Y; Sun Z; Yin M
Biomed Pharmacother; 2023 Nov; 167():115611. PubMed ID: 37778274
[TBL] [Abstract][Full Text] [Related]
62. Deucravacitinib in the treatment of psoriasis.
Estevinho T; Lé AM; Torres T
J Dermatolog Treat; 2023 Dec; 34(1):2154122. PubMed ID: 36453809
[TBL] [Abstract][Full Text] [Related]
63. TYK 2 inhibitors for the treatment of dermatologic conditions: the evolution of JAK inhibitors.
Jo CE; Gooderham M; Beecker J
Int J Dermatol; 2022 Feb; 61(2):139-147. PubMed ID: 33929045
[TBL] [Abstract][Full Text] [Related]
64. Deucravacitinib for the treatment of psoriatic arthritis: the evidence so far.
Martins A; Lé AM; Torres T
Drugs Context; 2023; 12():. PubMed ID: 37168876
[TBL] [Abstract][Full Text] [Related]
65. Tyk2 is a therapeutic target for psoriasis-like skin inflammation.
Ishizaki M; Muromoto R; Akimoto T; Sekine Y; Kon S; Diwan M; Maeda H; Togi S; Shimoda K; Oritani K; Matsuda T
Int Immunol; 2014 May; 26(5):257-67. PubMed ID: 24345760
[TBL] [Abstract][Full Text] [Related]
66. TYK2 as a therapeutic target in the treatment of autoimmune and inflammatory diseases.
Gonciarz M; Pawlak-Buś K; Leszczyński P; Owczarek W
Immunotherapy; 2021 Sep; 13(13):1135-1150. PubMed ID: 34235974
[TBL] [Abstract][Full Text] [Related]
67. Efficacy and safety of selective TYK2 inhibitor, deucravacitinib, in a phase II trial in psoriatic arthritis.
Mease PJ; Deodhar AA; van der Heijde D; Behrens F; Kivitz AJ; Neal J; Kim J; Singhal S; Nowak M; Banerjee S
Ann Rheum Dis; 2022 Jun; 81(6):815-822. PubMed ID: 35241426
[TBL] [Abstract][Full Text] [Related]
68. Therapeutic Advantage of Tyk2 Inhibition for Treating Autoimmune and Chronic Inflammatory Diseases.
Muromoto R; Shimoda K; Oritani K; Matsuda T
Biol Pharm Bull; 2021; 44(11):1585-1592. PubMed ID: 34719635
[TBL] [Abstract][Full Text] [Related]
69. Association between TYK2 polymorphisms and susceptibility to autoimmune rheumatic diseases: a meta-analysis.
Lee YH; Bae SC
Lupus; 2016 Oct; 25(12):1307-14. PubMed ID: 26980740
[TBL] [Abstract][Full Text] [Related]
70. Discovery of a Potent and Selective Tyrosine Kinase 2 Inhibitor: TAK-279.
Leit S; Greenwood J; Carriero S; Mondal S; Abel R; Ashwell M; Blanchette H; Boyles NA; Cartwright M; Collis A; Feng S; Ghanakota P; Harriman GC; Hosagrahara V; Kaila N; Kapeller R; Rafi SB; Romero DL; Tarantino PM; Timaniya J; Toms AV; Wester RT; Westlin W; Srivastava B; Miao W; Tummino P; McElwee JJ; Edmondson SD; Masse CE
J Med Chem; 2023 Aug; 66(15):10473-10496. PubMed ID: 37427891
[TBL] [Abstract][Full Text] [Related]
71. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.
Sbidian E; Chaimani A; Garcia-Doval I; Do G; Hua C; Mazaud C; Droitcourt C; Hughes C; Ingram JR; Naldi L; Chosidow O; Le Cleach L
Cochrane Database Syst Rev; 2017 Dec; 12(12):CD011535. PubMed ID: 29271481
[TBL] [Abstract][Full Text] [Related]
72. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.
Sbidian E; Chaimani A; Afach S; Doney L; Dressler C; Hua C; Mazaud C; Phan C; Hughes C; Riddle D; Naldi L; Garcia-Doval I; Le Cleach L
Cochrane Database Syst Rev; 2020 Jan; 1(1):CD011535. PubMed ID: 31917873
[TBL] [Abstract][Full Text] [Related]
73. Dependency on the TYK2/STAT1/MCL1 axis in anaplastic large cell lymphoma.
Prutsch N; Gurnhofer E; Suske T; Liang HC; Schlederer M; Roos S; Wu LC; Simonitsch-Klupp I; Alvarez-Hernandez A; Kornauth C; Leone DA; Svinka J; Eferl R; Limberger T; Aufinger A; Shirsath N; Wolf P; Hielscher T; Sternberg C; Aberger F; Schmoellerl J; Stoiber D; Strobl B; Jäger U; Staber PB; Grebien F; Moriggl R; Müller M; Inghirami GG; Sanda T; Look AT; Turner SD; Kenner L; Merkel O
Leukemia; 2019 Mar; 33(3):696-709. PubMed ID: 30131584
[TBL] [Abstract][Full Text] [Related]
74. Tyrosine kinase 2 - Surveillant of tumours and bona fide oncogene.
Leitner NR; Witalisz-Siepracka A; Strobl B; Müller M
Cytokine; 2017 Jan; 89():209-218. PubMed ID: 26631911
[TBL] [Abstract][Full Text] [Related]
75. JAK/STAT/SOCS-signaling pathway and colon and rectal cancer.
Slattery ML; Lundgreen A; Kadlubar SA; Bondurant KL; Wolff RK
Mol Carcinog; 2013 Feb; 52(2):155-66. PubMed ID: 22121102
[TBL] [Abstract][Full Text] [Related]
76. Molecular and Cellular Responses to the TYK2/JAK1 Inhibitor PF-06700841 Reveal Reduction of Skin Inflammation in Plaque Psoriasis.
Page KM; Suarez-Farinas M; Suprun M; Zhang W; Garcet S; Fuentes-Duculan J; Li X; Scaramozza M; Kieras E; Banfield C; Clark JD; Fensome A; Krueger JG; Peeva E
J Invest Dermatol; 2020 Aug; 140(8):1546-1555.e4. PubMed ID: 31972249
[TBL] [Abstract][Full Text] [Related]
77. A rare variant of the TYK2 gene is confirmed to be associated with multiple sclerosis.
Mero IL; Lorentzen AR; Ban M; Smestad C; Celius EG; Aarseth JH; Myhr KM; Link J; Hillert J; Olsson T; Kockum I; Masterman T; Oturai AB; Søndergaard HB; Sellebjerg F; Saarela J; Kemppinen A; Elovaara I; Spurkland A; Dudbridge F; Lie BA; Harbo HF
Eur J Hum Genet; 2010 Apr; 18(4):502-4. PubMed ID: 19888296
[TBL] [Abstract][Full Text] [Related]
78. TYK2 in Immune Responses and Treatment of Psoriasis.
Shang L; Cao J; Zhao S; Zhang J; He Y
J Inflamm Res; 2022; 15():5373-5385. PubMed ID: 36147687
[TBL] [Abstract][Full Text] [Related]
79. Discovery of GLPG3667, a Selective ATP Competitive Tyrosine Kinase 2 Inhibitor for the Treatment of Autoimmune Diseases.
Mammoliti O; Martina S; Claes P; Coti G; Blanque R; Jagerschmidt C; Shoji K; Borgonovi M; De Vos S; Marsais F; Oste L; Quinton E; López-Ramos M; Amantini D; Brys R; Jimenez JM; Galien R; van der Plas S
J Med Chem; 2024 Jun; 67(11):8545-8568. PubMed ID: 38805213
[TBL] [Abstract][Full Text] [Related]
80. Influence of TYK2 in systemic sclerosis susceptibility: a new locus in the IL-12 pathway.
López-Isac E; Campillo-Davo D; Bossini-Castillo L; Guerra SG; Assassi S; Simeón CP; Carreira P; Ortego-Centeno N; García de la Peña P; ; Beretta L; Santaniello A; Bellocchi C; Lunardi C; Moroncini G; Gabrielli A; Riemekasten G; Witte T; Hunzelmann N; Kreuter A; Distler JH; Voskuyl AE; de Vries-Bouwstra J; Herrick A; Worthington J; Denton CP; Fonseca C; Radstake TR; Mayes MD; Martín J
Ann Rheum Dis; 2016 Aug; 75(8):1521-6. PubMed ID: 26338038
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
